Skip to main content

Immunophotodynamic therapy of cancer: concepts and applications

Cel

Photodynamic therapy of cancer, i.e. the generation of reactive oxygen species in the tumour environment which follows the irradiation of suitable photosensitising molecules, is an attractive modality for the selective ablation of inoperable superficial neoplastic lesions, such as certain head and neck, gastrointestinal, urogenital and gynecological tumours. It is likely that the scope and efficacy of photodynamic therapy could be enhanced by: - the availability of novel efficient photosensitizers which absorb at in the red / near infrared region of the spectrum, where light penetration of tissues is maximal - the use of antibody-photosensitizer conjugates or conceptually related innovative delivery systems, which concentrate the photosensitising molecules at suitable neoplastic sites.

The tumour neo-vasculature appears to be an attractive target, since the selective delivery of photosensitizers may occlude the tumour blood vessels, thus causing an avalanche of tumour cell deaths. In this Project, we have put together a network of academic research groups and companies, for the development of antibody-based targeted photodynamic therapy modalities. The planned research activity starts with the synthesis of novel photosensitising molecules suitable for conjugation to antibodies, and with the identification of novel human monoclonal antibodies, capable of a selective targeting of the tumour neovasculature for immuno-PDT applications.

Following an extensive in vitro characterization of the most promising antibody-photosensitizer conjugates (including an innovative delivery concept in which photosensitizers are non-covalently bound to the antibody), the therapeutic potential of the best conjugates will be tested in rodent models of cancer, paving the way to future clinical applications. Some of the members of our network have collaborated before, and have brought three antibody derivatives into advanced clinical and industrial development in the oncology field.

Zaproszenie do składania wniosków

FP6-2005-LIFESCIHEALTH-7
Zobacz inne projekty w ramach tego zaproszenia

Koordynator

PHILOGEN SPA
Adres
La Lizza 7
Siena
Włochy

Zobacz na mapie

Uczestnicy (8)

UNIVERSITY OF HULL
United Kingdom
Adres
Cottingham Road
Kingston Upon Hull

Zobacz na mapie

PHOTOBIOTICS LTD
United Kingdom
Adres
21 Wilson Street
London

Zobacz na mapie

CENTRO BIOTECNOLOGIE AVANZATE
Włochy
Adres
Largo R. Benzi 10
Genoa

Zobacz na mapie

RUPRECHT-KARLS-UNIVERITAET HEIDELBERG
Niemcy
Adres
Seminarstrasse 2
Heidelberg

Zobacz na mapie

IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE
United Kingdom
Adres
Exhibition Road, South Kensington Campus
London

Zobacz na mapie

TROJANTEC LTD
Cypr
Adres
32 Acropoleus Avenue
Nicosia

Zobacz na mapie

CHARITÈ - UNIVERSITAETMEDIZIN BERLIN
Niemcy
Adres
Chariteplatz 1
Berlin

Zobacz na mapie

EIDGENÖSSISCHE TECHNISCHE HOCHSCHULE ZÜRICH
Szwajcaria
Adres
Reamistrasse 101
Zurich

Zobacz na mapie